PMID: 3756784Oct 15, 1986Paper

Stage I-II follicular lymphoma. Treatment results for 76 patients

Cancer
P McLaughlinF Cabanillas

Abstract

Clinical features and treatment results are analyzed for 76 patients with Stage I-II follicular lymphoma seen between 1974 and 1981. During this period, 66% of the patients received involved-field radiotherapy (XRT) alone, and 34% received chemotherapy with or without XRT. At 5 years, the overall survival was 67%, the cause-specific survival was 73%, and the relapse-free survival (RFS) was 48%, with no relapses to date among nine patients followed beyond 60 months. Adverse prognostic features for survival included extranodal disease and elevated serum lactate dehydrogenase. For RFS, adverse features included extranodal disease and bulky abdominal disease. The RFS was significantly better for patients receiving chemotherapy with or without XRT than for XRT alone (64% versus 37% at 5 years, P = 0.02), despite a higher frequency of adverse prognostic features in the chemotherapy-treated group. About 50% of Stage I-II follicular lymphoma patients may be curable, and the inclusion of chemotherapy in the initial treatment may increase the potentially curable fraction.

References

Jan 1, 1979·Annals of Internal Medicine·C S Portlock, S A Rosenberg
Aug 1, 1976·Annals of Internal Medicine·B A ChabnerV T DeVita
Apr 1, 1976·Cancer·R QaziJ C Long
Jul 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianF F Cabanillas
Jul 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S B ParyaniH S Kaplan
Dec 6, 1984·The New England Journal of Medicine·B R SmithK A Ault
Dec 6, 1984·The New England Journal of Medicine·S J Horning, S A Rosenberg
Apr 1, 1984·International Journal of Radiation Oncology, Biology, Physics·M K GospodarowiczT Chua
Feb 1, 1980·International Journal of Radiation Oncology, Biology, Physics·S MonfardiniA Lattuada

❮ Previous
Next ❯

Citations

Sep 1, 1995·Medical Oncology·F B Hagemeister
May 15, 2009·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Hans Theodor EichRolf-Peter Müller
Apr 1, 2010·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Frank HeinzelmannMartin Weinmann
Jun 23, 2007·Annals of Hematology·Aylin Fidan KorcumGulgun Erdogan
Mar 14, 2007·Digestive Diseases and Sciences·Boris SapoznikovYaron Niv
Sep 1, 1995·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·S PendleburyA Horwich
Jan 1, 1997·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·E J Sawyer, A R Timothy
Feb 11, 1998·International Journal of Radiation Oncology, Biology, Physics·P M RichaudB Hoerni
May 29, 1999·International Journal of Radiation Oncology, Biology, Physics·S S KamathN P Mendenhall
Jun 23, 2000·Critical Reviews in Oncology/hematology·P SoubeyranH Eghbali
Sep 5, 2001·Australasian Radiology·M P MacManus, J F Seymour
Jul 10, 1999·Current Opinion in Hematology·R G Bociek, J O Armitage
Jul 24, 2012·Current Opinion in Oncology·Caron A Jacobson, Arnold S Freedman
Feb 28, 2007·Leukemia & Lymphoma·Koen van Besien, Harry Schouten
Oct 15, 2008·Leukemia & Lymphoma·Christian BuskeWyndham Wilson
Oct 1, 1993·Leukemia & Lymphoma·D F Moore, F Cabanillas
Apr 1, 1994·Leukemia & Lymphoma·J VuckovicV Capkun
Apr 1, 1995·Leukemia & Lymphoma·H M Lazarus
Mar 1, 1989·International Journal of Radiation Oncology, Biology, Physics·S ReddyF R Hendrickson
May 30, 2006·Hematology/oncology Clinics of North America·Chung K Lee
Mar 7, 2009·Hematological Oncology·R L M Haas
Mar 25, 2008·Critical Reviews in Oncology/hematology·Umberto VitoloSilvia Montoto
Jan 1, 1992·Critical Reviews in Oncology/hematology·M R MirzaL Specht
Jun 1, 1987·Baillière's Clinical Haematology·J W Sweetenham, C J Williams
Nov 1, 1987·Current Problems in Cancer·R T Hoppe
Oct 1, 1988·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·P SoubeyranB Hoerni
May 23, 2003·The Korean Journal of Internal Medicine·Kil Chan Oh, Dae Young Zang
Mar 15, 2011·International Journal of Radiation Oncology, Biology, Physics·Christine RossierMahmut Ozsahin
May 26, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pier Luigi ZinzaniMichele Baccarani
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John F SeymourPeter McLaughlin
Oct 19, 2007·The Cochrane Database of Systematic Reviews·H SchulzA Engert
May 1, 1994·The Journal of Urology·Y H Salem, H C Miller

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.